<DOC>
	<DOCNO>NCT01185821</DOCNO>
	<brief_summary>This blind extension study design offer patient relapsing-remitting MS complete core study CBAF312A2201 access BAF312 enter open label study . It provide data long-term safety , tolerability efficacy BAF312 patient population .</brief_summary>
	<brief_title>Long-term Safety , Tolerability Efficacy BAF312 Given Orally Patients With Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Immune System Diseases</mesh_term>
	<mesh_term>Autoimmune Diseases Nervous System</mesh_term>
	<criteria>Patients complete core study BAF312A2201 Written inform consent provide assessment extension study Female patient risk become pregnant must negative pregnancy test use simultaneously two form effective contraception Newly diagnose systemic disease MS ( may require immunosuppressive treatment ) Malignancies , diabetes , significant cardiovascular pulmonary disease condition Active infection Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>56 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing remit Multiple Sclerosis</keyword>
	<keyword>Demyelinating Autoimmune Diseases</keyword>
</DOC>